Badoux XC, Keating MJ, Wen S, et al: Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood 118:3489-3498, 2011.
Byrd JC, Blum KA, Burger JA, et al: Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL): Interim results of a phase I/IIb study. J Clin Oncol 29(suppl): abstract 6508, 2011.
Byrd JC, Kipps TJ, Flinn IW, et al: Phase I/II study of lumiliximab combined with fludarabine, cyclophosphamide(Drug information on cyclophosphamide), and rituximab(Drug information on rituximab) in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 115:489–495, 2010.
Byrd JC, Peterson BL, Morrison VA, et al: Randomized phase II study of fludarabine with concurrent vs sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 101:6–14, 2003.
Calin GA, Ferracin M, Cimmino A, et al: A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353:1793–1801, 2005.
Catovsky D, Richards S, Matutes E, et al: Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): A randomised controlled trial. Lancet 370:230–239, 2007.
Chanan-Khan A, Miller KC, Musial L, et al: Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study. J Clin Oncol 24:5343–5349, 2006.
Crespo M, Bosch F, Villamor N, et al: ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 348:1764–1775, 2003.
Coutre SE, Byrd JC, Furman RR, et al: Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3--kinase P110d, in patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 29(suppl): abstract 6631, 2011.
Damle RN, Wasil T, Fais F, et al: Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94:1840–1847, 1999.
Eichhorst BF, Busch R, Hopfinger G, et al: Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107:885–891, 2006.
Eichhorst BF, Busch R, Stilgenbauer S, et al: First-line therapy with fludarabine compared with chlorambucil(Drug information on chlorambucil) does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 114:3382-3391, 2009.
Else M, Ruchlemer R, Osuji N, et al: Long remissions in hairy cell leukemia with purine analogs. Cancer 104:2442–2448, 2005.
Ferrajoli A, Lee BN, Schlette EJ, et al: Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 111:5291–5297, 2008.
Ferrajoli A, Badoux XC, O'Brien S, et al: Combination therapy with lenalidomide and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL). Blood 114: abstract 206, 2009.
Flinn IW, Neuberg DS, Grever MR, et al: Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 25:793–798, 2007.
Foon KA, Boyiadzis M, Land SR, et al: Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high-dose rituximab in previously untreated patients with CLL. J Clin Oncol 27:498–503, 2009.
Hallek M, Fingerle-Rowson G, Fink A-M, et al: Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL). Blood 112: abstract 325, 2008.
Hallek M, Fischer K, Fingerle-Rowson G, et al: Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet 376:1164-1174, 2010.
Hillmen P, Skotnicki AB, Robak T, et al: Alemtuzumab(Drug information on alemtuzumab) compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 25:5616–5623, 2007.
Kay NE, Geyer SM, Call TG, et al: Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 109:405–411, 2007.
Keating MJ, O'Brien S, Albitar M, et al: Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as intital therapy for chronic lymphocytic leukemia. J Clin Oncol 23:4079–4088, 2005.
Knauf WU, Lissichkov T, Aldaoud A, et al: Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 27:4378–4384, 2009.
Lamanna N, Kalaycio M, Maslak P, et al: Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 24:1575–1581, 2006.
Landgren O, Albitar M, Ma W, et al: B-cell clones as early markers for chronic lymphocytic leukemia. N Engl J Med 60: 659–667, 2009.
Lin KI, Tam CS, Keating MJ, et al: Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide and rituximab (FCR) or related chemoimmunotherapy regimens. Blood 113:3168–3171, 2009.
Lin TS, Ruppert AS, Johnson AJ, et al: Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 27: 6012–6018, 2009.
Lundin J, Kimby E, Bjorkholm M, et al: Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100:768–773, 2002.
Moreton P, Kennedy B, Lucas G, et al: Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 23:2971–2979, 2005.
Morschhauser F, Cartron G, Lamy T, et al: Phase I study of RO5072759 (GA101) in relapsed/refractory chronic lymphocytic leukemia. Blood 114: abstract 884, 2009.
Rai KR, Peterson BL, Appelbaum FR, et al: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343:1750–1757, 2000.
Ravandi F, O'Brien S, Jorgensen J, et al: Phase II study of cladribine(Drug information on cladribine) followed by rituximab in patients with hairy cell leukemia. Blood 118:3818-3823, 2011.
Siegel R, Ward E, Brawley O, Jemal A: Cancer statistics 2011. CA Cancer J Clin 61:212-236, 2011.
Wierda W, O'Brien S, Wen S, et al: Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 23:4070–4078, 2005.
Wierda WG, Kipps TJ, Mayer J, et al: Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 28:1749–1755, 2010.
Abbreviations in this chapter
BMRC = British Medical Research Council; ECOG = Eastern Cooperative Oncology Group; FDA = US Food and Drug Administration; GCLLSG = German CLL Study Group; IWCLL = International Workshop on Chronic Lymphocytic Leukemia; NCI = National Cancer Institute